Variables | Overall, n = 497 | Acinetobacter baumannii isolated | p value | Hazard ratio (95% CI) | |
---|---|---|---|---|---|
Yes, n = 159 | No, n = 338 | ||||
Median age, y (IQR) | 60.1 (49–73) | 61 (50–74) | 59.6 (49–73) | 0.444 | 1.004 (0.994–1.013) |
Sex, no. (%) | |||||
F | 160 (32.2) | 44 (27.7) | 116 (34.3) | Referent | |
M | 337 (67.8) | 115 (72.3) | 222 (65.7) | 0.139 | 0.769 (0.544–1.089) |
Mean Charlson comorbidity index, (SD) | 4.26 (2.12) | 4.40 (2.14) | 4.20 (2.11) | 0.293 | 1.038 (0.968–1.113) |
Underlying conditions, no. (%) | |||||
Cardiovascular diseases | 200 (40.2) | 79 (49.7) | 121 (358) | 0.003 | 1.596 (1.169–2.178) |
Chronic renal insufficiency | 179 (36.0) | 71 (44.7) | 108 (32.0) | 0.011 | 1.504 (1.200–2.056) |
COPD and asthma | 176 (35.4) | 71 (44.7) | 105 (31.1) | 0.005 | 1.570 (1.148–2.146) |
Type 2 diabetes mellitus | 116 (23.3) | 46 (28.9) | 70 (20.7) | 0.057 | 1.395 (0.990–1.965) |
Solid tumor | 100 (20.1) | 36 (22.6) | 64 (18.9) | 0.363 | 1.188 (0.820–1.723) |
Hematologic malignancy | 31 (6.2) | 8 (5.0) | 23 (6.8) | 0.497 | 0.781 (0.384–1.591) |
Past inhaled steroids use for chronic conditions | 47 (9.5) | 17 (10.7) | 30 (8.9) | 0.450 | 1.214 (0.734–2.007) |
Current or former smoker | 187 (37.6) | 74 (46.5) | 113 (33.4) | 0.005 | 1.565 (1.146–2.138) |
Postoperative admission | 142 (28.6) | 38 (23.9) | 104 (30.8) | 0.134 | 0.757 (0.526–1.090) |
Treatment, no. (%) | |||||
No aerosol inhalation | 137 (27.6) | 33 (20.8) | 104 (30.8) | Referent | |
Glucocorticoid aerosol inhalation | 262 (52.7) | 107 (67.3) | 155 (45.9) | 0.002 | 1.860 (1.264–2.738) |
Aerosol inhalation without glucocorticoid | 98 (19.7) | 19 (11.9) | 79 (23.4) | 0.337 | 0.760 (0.433–1.332) |
Broad-spectrum antimicrobial drugs, ≥7 d | 417 (83.9) | 157 (98.7) | 260 (76.9) | <0.001 | 9.539 (4.595–18.795) |
Invasive mechanical ventilation, ≥5 d | 221 (44.5) | 112 (70.4) | 109 (32.2) | <0.001 | 3.452 (2.453–4.858) |
Urethral catheter placement, ≥3 d | 493 (99.2) | 158 (99.4) | 335 (99.1) | 0.875 | 1.171 (0.164–8.361) |
Vasopressor treatment, ≥3 d | 75 (15.1) | 42 (26.4) | 33 (9.8) | <0.001 | 2.634 (1.850–3.750) |
Renal dialysis, ≥3 d | 84 (16.9) | 34 (21.4) | 50 (14.8) | 0.063 | 1.432 (0.980–2.093) |
APACHE II score, mean (SD) | 18.18 (6.03) | 18.98 (6.44) | 17.80 (5.80) | 0.053 | 1.026 (1.000–1.053) |
Median length of ICU stay, d (IQR) | 15 (7–23) | 20 (10–28) | 13 (6–20) | 0.057 | 1.005 (1.000–1.010) |
Table 1. Univariate analysis of risk factors for Acinetobacter baumannii among patients during invasive mechanical ventilation, China*
*APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range.
Variables | p value | Hazard ratio (95% CI) |
---|---|---|
Underlying conditions | ||
Cardiovascular diseases | 0.054 | 1.394 (0.994–1.955) |
Chronic renal insufficiency | 0.730 | 0.937 (0.648–1.356) |
COPD and asthma | 0.132 | 1.299 (0.924–1.825) |
Type 2 diabetes mellitus | 0.325 | 1.197 (0.837–1.714) |
Current or former smoker | 0.098 | 1.307 (0.951–1.797) |
Treatment | ||
No aerosol inhalation | Referent | |
Glucocorticoid aerosol inhalation | 0.038 | 1.528 (1.024–2.278) |
Aerosol inhalation without glucocorticoid | 0.524 | 0.829 (0.467–1.475) |
Broad-spectrum antimicrobial drugs, ≥7 d | 0.001 | 7.238 (2.758–15.788) |
Invasive mechanical ventilation, ≥5 d | 0.001 | 2.381 (1.664–3.405) |
Vasopressor treatment, ≥3 d | <0.001 | 2.060 (1.402–3.028) |
Renal dialysis, ≥3 d | 0.841 | 1.046 (0.675–1.620) |
APACHE II score | 0.586 | 0.992 (0.965–1.020) |
Table 2. Multivariate analysis of risk factors for Acinetobacter baumannii among patients during invasive mechanical ventilation, China*
*Results are from model 2; only variables with p<0.1 in univariate analysis were included. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease.
Variables | p value | Hazard ratio (95% CI) |
---|---|---|
Underlying conditions | ||
Cardiovascular diseases | 0.117 | 1.361 (0.926–2.001) |
Chronic renal insufficiency | 0.800 | 1.052 (0.712–1.554) |
Type 2 diabetes mellitus | 0.243 | 1.271 (0.850–1.899) |
Current or former smoker | 0.051 | 1.442 (0.998–2.083) |
Treatment | ||
Glucocorticoid aerosol inhalation | 0.032 | 1.489 (1.036–2.141) |
Broad-spectrum antimicrobial drugs, ≥7 d | 0.004 | 6.315 (2.543–13.921) |
Invasive mechanical ventilation, ≥5 d | <0.001 | 2.388 (1.614–3.534) |
Vasopressor treatment, ≥3 d | 0.501 | 1.188 (0.719–1.963) |
APACHE II score | 0.363 | 1.014 (0.984–1.045) |
Table 3. Multivariate analysis of risk factors for Acinetobacter baumannii among propensity-matched patient cohort during invasive mechanical ventilation, China*
*Only variables with p<0.1 in univariate analysis of the propensity-matched cohort were included. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for primary care physicians, infectious disease specialists, critical care specialists, and other physicians who care for patients receiving invasive mechanical ventilation (IMV).
The goal of this activity is for learners to be better able to discuss how aerosol treatments may affect the risk for infection with Acinetobacter baumannii (AB).
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 11/17/2022
Valid for credit through: 11/17/2023, 11:59 PM EST
processing....
Acinetobacter baumannii is a nosocomial pathogen associated with severe illness and death. Glucocorticoid aerosol is a common inhalation therapy in patients receiving invasive mechanical ventilation. We conducted a prospective cohort study to analyze the association between glucocorticoid aerosol therapy and A. baumannii isolation from ventilator patients in China. Of 497 enrolled patients, 262 (52.7%) received glucocorticoid aerosol, and A. baumannii was isolated from 159 (32.0%). Glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation (hazard ratio 1.5, 95% CI 1.02–2.28; p = 0.038). Patients receiving glucocorticoid aerosol had a higher cumulative hazard for A. baumannii isolation and analysis showed that glucocorticoid aerosol therapy increased A. baumannii isolation in most subpopulations. Glucocorticoid aerosol was not a direct risk factor for 30-day mortality, but A. baumannii isolation was independently associated with 30-day mortality in ventilator patients. Physicians should consider potential A. baumannii infection when prescribing glucocorticoid aerosol therapy.
Acinetobacter baumannii, a gram-negative coccobacillus, is a major nosocomial pathogen worldwide. A. baumannii is particularly challenging in intensive care units (ICUs). According to the Extended Prevalence of Infection in Intensive Care study, aimed at providing information on the prevalence of infection in ICUs worldwide, Acinetobacter spp. constituted 8.8% of all culture-positive ICU infections in 2007[1], which increased to 11.4% in 2017[2]. However, infection rates differed markedly, ranging from 1.0% in North America to 25.6% in Asia and the Middle East and 22.9% in eastern Europe[2]. Patients on invasive mechanical ventilation are particularly vulnerable to A. baumannii infection and colonization due to airway barrier destruction and bacterial virulence factors such as motility, epithelial adherence, and biofilm formation that enable A. baumannii colonization in the airways[3,4]. A. baumannii in patient airways is associated with longer hospitalization, higher medical expenses, and increased mortality rates[5–7]. Identifying risk factors for A. baumannii infection is crucial for implementing preventive measures and decreasing overall illness and death.
Aerosol inhalation is widely used in patients requiring mechanical ventilation. Glucocorticoids are frequently administered during aerosol therapy, especially in China[8–10]. Compared with systemic application, aerosol therapy has several advantages, including targeted delivery to the lungs, faster response, and fewer systemic side effects[11,12]. However, the aerosols and droplets generated during aerosol inhalation can become sources of respiratory pathogens[13], and inhaled glucocorticoids might suppress pulmonary immunity[14], which could increase the opportunity for nosocomial acquisition. Inhaled corticosteroids are associated with an increased risk for pneumonia in patients with chronic obstructive pulmonary disease (COPD)[15]. However, the effects of glucocorticoid aerosol inhalation on nosocomial infection risk has not been clearly elucidated.
Glucocorticoid aerosol therapy is mainly indicated for patients with asthma, COPD[16], acute respiratory distress syndrome (ARDS)[17], and some pathophysiological conditions, such as airway hyperresponsiveness[18], hyperinflammation, and mucosal edema[19]. In the past decade, use of glucocorticoid aerosol therapy has increased in hospitals in China; on average, >40% of patients on mechanical ventilation receive this therapy[9]. In addition, a market analysis determined that aerosolized glucocorticoid sales in China were almost 3-fold higher in 2018 than in 2012[20].
Although epidemiology has demonstrated a slow increase in A. baumannii infection globally over the past decade[1,2], the increase in A. baumannii incidence in China appears to have outpaced increases in other regions worldwide[21–23]. According to the China Antimicrobial Surveillance Network (CHINET), a national surveillance of the trends of bacterial strains isolated from the major hospitals in China, the number of Acinetobacter spp. strains increased by 2.7-fold in 2018 compared with 2012[23,24]. Previously, we reported a marked increase in the incidence of A. baumannii–related bloodstream infections and incidence of pneumonia-related A. baumannii infections in ICUs in China that were 3.2-fold higher during 2017–2018 than during 2011–2012[25]. A. baumannii was the most frequent bacterial isolate in ventilator-associated pneumonia in China, and rates were 35.7%–52.7%[26,27]. Furthermore, the incidence of the drug-resistant phenotype of A. baumannii is high. According to CHINET reports, carbapenem-resistant A. baumannii strains increased from 31% in 2005 to 66.7% in 2014[28], then to ≈80% in 2018[29]. We previously reported that carbapenem resistance rates in ICUs in China increased from 25% during 2011–2012 to 95.7% during 2017–2018[25]. A multicenter study of ICUs in China reported that multidrug-resistant (MDR) A. baumannii was detected in 40% of all cases[30].
We hypothesized that increased use of glucocorticoid aerosol therapy might contribute to increased A. baumannii incidence. Therefore, we performed a prospective cohort study of critically ill patients receiving invasive mechanical ventilation in China to determine whether use of aerosolized glucocorticoid increased the risk for A. baumannii isolation.